The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •1. Uncontrolled hypertension (systolic ≥140mmHg and/or diastolic ≥90mmHg after medication treatment); Poor control of blood sugar.
• •2. Acute phase of cerebral infarction, or recovery period \<2 months.
• •3. A variety of factors that affect the absorption of oral medications (such as inability to swallow, nausea and vomiting, chronic diarrhea, intestinal obstruction, etc.)
• •4. Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions, and fecal occult blood (++); (2) a history of melena and hematemesis within 2 months. Simple fecal occult blood (+) is not an exclusion criterion.
• •5. Coagulation abnormality (INR\>1.5×ULN, APTT\>1.5×ULN), with bleeding tendency.
• •6. Urine protein ≥ ++ or confirmed 24-hour urine protein quantitation \> 1.0 g.
• •7. Pregnant or lactating women.
• •8. Severe liver and kidney dysfunction (grade 4) .
• •9. Allergic to any ingredient of apatinib mesylate.
• •10. A history of abuse of psychotropic substances and are unable to quit smoking or mental disorders.
• •11. According to the investigator's judgment, people with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study.
• •12. Surgery, major trauma or fracture, within 4 weeks before the treatment or unhealed wound before treatment.
• •13. Severe heart disease, such as grade III or above (NYHA standard) congestive heart failure, grade III or above (CCS standard) angina, a history of myocardial infarction within 6 months before the treatment, or medication treated arrhythmia.
• •14. Brain metastasis and meningeal metastasis.